首页> 外文期刊>Current medicinal chemistry >Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional chinese medicine origin for the treatment of Alzheimer's disease.
【24h】

Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional chinese medicine origin for the treatment of Alzheimer's disease.

机译:石杉碱甲的临床,药理,化学和结构生物学研究进展:一种中药治疗阿尔茨海默氏病的中药。

获取原文
获取原文并翻译 | 示例
       

摘要

HupA is a potent, reversible AChEI, which crosses the blood-brain barrier smoothly, and shows high specificity for AChE with a prolonged biological half-life. It has been approved as the drug for the treatment of AD in China, and marketed in USA as a dietary supplement. HupA has been the subject of investigations by an ever-increasing number of researchers since 1980's. In the last four years, HupA has been further studied in many aspects such as the chemical synthesis, structural modification, structure-activity relationship, various biological effects, and mechanisms of action. A number of papers dealing with the computational modeling and X-ray crystallographic studies of HupA-AChE complex have also been published. This review represents a comprehensive documentation of the progress in the studies on HupA during the period of 1999-2002.
机译:HupA是一种有效的,可逆的AChEI,可平滑地穿过血脑屏障,并显示出对AChE的高特异性,并具有延长的生物半衰期。它已在中国被批准为治疗AD的药物,并在美国作为膳食补充剂销售。自1980年代以来,HupA一直是越来越多的研究人员进行调查的对象。在过去的四年中,HupA已在许多方面进行了进一步研究,例如化学合成,结构修饰,结构-活性关系,各种生物学效应和作用机理。关于HupA-AChE复合物的计算模型和X射线晶体学研究的许多论文也已经发表。这次审查代表了关于1999-2002年期间HupA研究进展的全面文件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号